State Street Corp Avenue Therapeutics, Inc. Transaction History

State Street Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.41 - $7.11 $346,560 - $1.02 Million	-143,801 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.7 - $7.17 $184,240 - $281,064	39,200 Added 37.48%	143,801 $873,000
Q4 2020 Feb 16, 2021	BUY	$2.95 - $11.04 $92,290 - $345,386	31,285 Added 42.67%	104,601 $622,000
Q3 2020 Nov 10, 2020	BUY	$9.37 - $12.06 $59,705 - $76,846	6,372 Added 9.52%	73,316 $794,000
Q2 2020 Aug 14, 2020	BUY	$8.29 - $11.47 $554,965 - $767,847	66,944 New	66,944 $721,000

Ticker ATXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,127,720
Market Cap $9.25M
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.